

Half Year Review to June 2026 Continued Revenue Growth and Margin Improvement, Prolimmune Matter Resolved

ASX Announcement

31 August 2026


Highlights

- **Revenue Growth:** Group revenue rose 3.6% to \$2.99 million (1HFY25: \$2.89 million).
- **Improved Gross Margin:** Gross margin improved to 44.3% (1HFY25: 41.9%).
- **Supplements Division Momentum:** Sales of 12.2% to \$2.91 million, supported by an expanded marketplace presence and a stronger sales and marketing team.
- **Agriculture Orders Building:** Nano urea and poultry probiotic sales of \$23,484, progressing from trial runs toward more consistent orders.
- **Prolimmune Matter Resolved:** Following the WA Supreme Court's April 2026 judgment, the Company settled the matter for US\$1.8 million, with final payment made on 10 July 2026.
- **Net Loss:** Net loss of \$2.56 million (1HFY25: \$0.30 million), including approximately \$2.66 million in one-off costs related to the settlement of the Prolimmune matter. Excluding this item, the Group's underlying profit after tax for the period was approximately \$0.095 million.

Financial Performance

Holista Colltech Limited ("Holista" or "the Group") is pleased to present its Appendix 4D and interim financial results for the half year ended 30 June 2026.

- **Revenue Growth:** Group revenue grew 3.6% to \$2.99 million (1HFY25: \$2.89 million).
- **Gross Profit:** Gross profit reached \$1.33 million (1HFY25: \$1.210 million), with margin improving to 44.3% (1HFY25: 41.9%), supported by a favourable sales mix and ongoing cost control.
- **Net Loss:** The loss after income tax was \$2.56 million (1HFY25: \$0.30 million). Excluding approximately \$2.66 million in one-off costs related to settlement of the Prolimmune matter (see Corporate Update below), the Group's underlying profit after tax for the period was approximately \$0.095 million.



**All sales figures are subject to audit*

Divisional Performance

1. Dietary Supplements Division

- **Revenue:** Up 12.2% to \$2.91 million, continuing the recovery recorded in FY2025.
- **Drivers:** Resolution of a legacy returns issue, a \$128,000 favourable refund liability adjustment, and continued strengthening of the sales and marketing team.
- **Outlook:** During the period, Holista expanded onto TikTok Shop as a new marketplace channel and launched a refreshed e-commerce website, improving the online customer experience. To mark the 25th anniversary of the Pristin brand, and the Group has planned a series of marketing campaigns and activities throughout 2026.

2. Food Ingredients Division

- **Revenue:** \$29,963 (1HFY25: \$204,889), as the division's main customer moved through a privatisation process and adopted a more conservative inventory position.
- **Outlook:** The Group is developing a new food ingredient formulation which allows FDA-approved "sugar free" label claims with improved performance characteristics. This will broaden the division's product offering and customer base beyond its historical concentration.

3. Ovine Collagen Division

- **Revenue:** \$28,781 (1HFY25: \$90,394), consistent with the transition following the closure of the Collie facility.
- **Strategic Updates:** Further to the formation of a joint-venture with HKEX-listed Swang Chai Chuan Limited, the latter has contributed RM5.0 million. With these proceeds Ovicoll has completed the acquisition of land in Collie, Western Australia, for a proposed ovine collagen manufacturing facility. Planning and implementation activities remain ongoing, and the Group will provide further updates as material milestones are reached.

4. Infection Control/Agriculture Division

- **Revenue:** \$23,484, building on initial sales recorded in FY2025.

- **Status:** The division's nano urea and poultry probiotic products are progressing from test-run trials toward more consistent, repeat orders from agricultural customers. The Group is encouraged by progress heading into the second half.

Outlook and Strategic Priorities

Having resolved the Prolimmune matter and grown its digital and marketplace reach in Supplements this period, the Board has directed management to focus on consolidating recovery across the Group — through continued product innovation in Food Ingredients, progressing the manufacturing plans for ovine collagen, and converting trial orders from the Agriculture Segment into repeat business.

Corporate Update

- **Prolimmune Matter Resolved:** As announced on 22 April 2026, the Supreme Court of Western Australia granted summary judgment in favour of Prolimmune, enforcing the U.S. judgment debt of US\$2,063,141. The Company subsequently settled the matter in full for US\$1.8 million — a material discount to the total exposure — with final payment completed on 10 July 2026. The matter is now fully resolved. Further details of the judgment and settlement are set out in Note 11 (Contingent Liabilities) to the financial statements.
- **Subsequent Event – Convertible Loan:** On 9 July 2026, the Company entered into a binding term sheet for an unsecured convertible loan of \$370,724 from Powerwind Plantation Sdn Bhd (“Powerwind”), at 8% per annum interest, convertible into fully paid ordinary shares at A\$0.07 per share (5,296,055 shares), subject to shareholder approval, with proceeds applied towards the final settlement payment to Prolimmune.
- There were no changes to the Board during the half-year.

This announcement has been authorised for release by the Board of Directors of Holista Colltech Limited.

-ENDS-

About Holista Colltech Limited

Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions. Operating across four dynamic business divisions—Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control/Agriculture Solutions—Holista delivers cutting-edge products that blend nature and science for healthier lifestyles.

Our portfolio features leading nutritional supplements, patented low-GI food ingredients, premium disease-free ovine collagen, and eco-friendly, non-toxic sanitizers for everyday and industrial use. We are dedicated to sustainable, science-driven solutions that empower better living and create lasting value for our stakeholders worldwide.

For further information, please contact:

Our Investor Mailing list: investors@holistaco.com

General Enquiries: enquiries@holistaco.com

Australia

283 Rokeby Road
Subiaco WA 6008 Western Australia
Australia
P: +61 412 474 180

Malaysia

12th Floor, Amcorp Trade Centre, PJ
Tower No. 18, Persiaran Barat off Jalan
Timur 46000, Petaling Jaya, Malaysia
P: +603 7965 2828; F: +603 7965 2777

Holista Colltech Limited
Appendix 4D
Half-year report

1. Company details

Name of entity:	Holista Colltech Limited
ABN:	24 094 515 992
Reporting period:	For the half-year ended 30 June 2026
Previous period:	For the half-year ended 30 June 2025

2. Results for announcement to the market

			\$
Revenues from ordinary activities	Up	3.60% to	2,993,311
Loss from ordinary activities after tax attributable to the owners of Holista Colltech Limited	Up	769.42% to	(2,560,990)
Loss for the half-year attributable to the owners of Holista Colltech Limited	Up	769.42% to	(2,560,990)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The loss for the Group after providing for income tax and non-controlling interest amounted to \$2,560,990 (30 June 2025: \$294,564).

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>(0.81)</u>	<u>(0.63)</u>

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

The Group holds a 50% interest in Ovicoll Pty Ltd ("Ovicoll"), a joint venture established with Swang Chai Chuan Limited ("SCC") on 4 May 2026 to develop a collagen manufacturing facility in Collie, Western Australia. The Group's investment in Ovicoll arose from the contribution of intellectual property, which had a nil carrying value in the Group's accounting records. As a result, the carrying amount of the investment at 30 June 2026 is nil. Ovicoll incurred a loss of approximately \$64,000 for the period from incorporation to 30 June 2026. In accordance with AASB 128, the Group's 50% share of this loss (approximately \$32,000) has not been recognised, as the carrying amount of the investment has already been reduced to nil and the Group has no obligation to fund further losses. Refer to Note 15 for further details.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been reviewed by the auditors and the review report is attached as part of the Interim Report.

11. Attachments

Details of attachments (if any):

The Interim Report of Holista Colltech Limited for the half-year ended 30 June 2026 is attached.

Holista Colltech Limited

ABN 24 094 515 992

Interim Report - 30 June 2026

Holista Colltech Limited
Corporate directory
30 June 2026

Directors	Mr Lai Kwok Kin Mr Leong Man Loong Mr Gregory Pilant Mr Robert Gemelli Mr Sam Yee
Company secretary	Mr Jay Stephenson
Registered office and Principal place of business	Australia: 283 Rokeby Road Subiaco, WA 6008 Malaysia: Unit 1201, 12th Floor, Amcorp Trade Centre, PJ Tower No. 18, Persiaran Barat 46000 Petaling Jaya, Malaysia Telephone: +603 7965 2828 Facsimile: +603 7965 2777 Email: enquiries@holistaco.com Website: www.holistaco.com
Share register	Computershare Investor Services Pty Limited Level 17, 221 St Georges Terrace Perth WA 6000 Telephone: 1300 850 505 (investors within Australia) Telephone: +61 (0)3 9415 4000 Email: web.queries@computershare.com.au Website: www.investorcentre.com
Auditor	Stantons International Audit and Consulting Pty Ltd Level 2, 40 Kings Park Road West Perth WA 6005, Australia Telephone: +61(0)8 9481 3188 Facsimile: +61(0)8 9321 1204
Solicitors	Edwards Mac Scovell Level 1/8, St.Georges Terrace Perth WA 6005, Australia Telephone: +61(0)8 6245 0222
Bankers	National Australian Bank
Stock exchange listing	Holista Colltech Limited shares are listed on the Australian Securities Exchange (ASX code: HCT).

Holista Colltech Limited
Directors' report
30 June 2026

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of Holista Colltech Limited (referred to hereafter as 'Holista', the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 30 June 2026.

Directors

The following persons were directors of Holista Colltech Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Mr Lai Kwok Kin	Non-Executive Chairman
Mr Leong Man Loong	Executive Director and CEO
Mr Gregory Pilant	Non-Executive Director
Mr Robert Gemelli	Non-Executive Director
Mr Sam Yee	Non-Executive Director

Principal activities

The principal activities of the Group are the manufacture and sale of health-style products, focusing on the following core areas:

- Dietary Supplements
- Healthy Food Ingredients
- Ovine Collagen
- Infection Control / Agriculture

Dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

Operating and financial review

Holista Colltech Limited ("Holista" or "the Group") is pleased to present its Appendix 4D and interim financial results for the half year ended 30 June 2026.

Group revenue rose 3.6% to \$2.99 million (1HFY25: \$2.89 million), with gross profit reaching \$1.33 million as the gross margin improved to 44.3% (1HFY25: 41.9%). The loss after income tax was \$2.562 million (1HFY25: \$0.30 million). Excluding the ProlImmune legal settlement of \$2.595 million and related legal fees of \$62,000, the Group recorded an underlying profit after tax of approximately \$95,000 for the period.

During the interim financial period, the Group's four divisions performed as follows:

- Dietary Supplements
- Healthy Food Ingredients
- Ovine Collagen
- Infection Control / Agriculture

Divisional Performance

1. Dietary Supplements Division

- **Revenue:** Up 12.2% to \$2.91 million, continuing the recovery recorded in FY2025.
- **Drivers:** Resolution of a legacy returns issue, a \$128,000 favourable refund liability adjustment, and continued strengthening of the sales and marketing team.
- **Outlook:** During the period, Holista expanded onto TikTok Shop as a new marketplace channel and launched a refreshed e-commerce website, improving the online customer experience. To mark the 25th anniversary of the Pristin brand, and the Group has planned a series of marketing campaigns and activities throughout 2026.

2. Food Ingredients Division

- **Revenue:** \$29,963 (1HFY25: \$204,889), as the division's main customer moved through a privatisation process and adopted a more conservative inventory position.
- **Outlook:** The Group is developing a new food ingredient formulation which allows FDA-approved "sugar free" label claims with improved performance characteristics. This will broaden the division's product offering and customer base beyond its historical concentration.

3. Ovine Collagen Division

- **Revenue:** \$28,781 (1HFY25: \$90,394), consistent with the transition following the closure of the Collie facility.
- **Strategic Updates:** Further to the formation of a joint-venture with HKEX-listed Swang Chai Chuan Limited, the latter has contributed RM5.0 million. With these proceeds Ovicoll has completed the acquisition of land in Collie, Western Australia, for a proposed ovine collagen manufacturing facility. Planning and implementation activities remain ongoing, and the Group will provide further updates as material milestones are reached.

4. Infection Control/Agriculture Division

- **Revenue:** \$23,484, building on initial sales recorded in FY2025.
- **Status:** The division's nano urea and poultry probiotic products are progressing from test-run trials toward more consistent, repeat orders from agricultural customers. The Group is encouraged by progress heading into the second half.

Outlook and Strategic Priorities

Having resolved the Prolimmune matter and grown its digital and marketplace reach in Supplements this period, the Board has directed management to focus on consolidating recovery across the Group — through continued product innovation in Food Ingredients, progressing the manufacturing plans for ovine collagen, and converting trial orders from the Agriculture Segment into repeat business.

Corporate Update

- **Prolimmune Matter Resolved:** As announced on 22 April 2026, the Supreme Court of Western Australia granted summary judgment in favour of The Prolimmune Company, LLC ("Prolimmune"), enforcing the US judgment debt of US\$2,063,141.05. The Company subsequently settled the matter in full for US\$1.8 million — a material discount to the total exposure — with final payment of US\$800,000 was settled on 10 July 2026. The matter is now fully resolved. Further details are set out in Note 11 (Contingent Liabilities) to the financial statements.
- **Subsequent Event – Convertible Loan:** On 9 July 2026, the Company entered into a binding terms sheet for an unsecured convertible loan of \$370,724 from Powerwind Plantation Sdn Bhd ("Powerwind"), at 8% per annum interest, convertible into fully paid ordinary shares at \$0.07 per share (5,296,055 shares), subject to shareholder approval, with proceeds applied towards the final settlement payment to Prolimmune.
- There were no changes to the Board during the half-year.

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the Group during the financial half-year.

Future Developments, Prospects and Business Strategies

There are no other likely developments, future prospects and business strategies not included in this Directors' report.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

Holista Colltech Limited
Directors' report
30 June 2026

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors



Leong Man Loong
Executive Director and Chief Executive Officer

31 August 2026



PO Box 1908
West Perth WA 6872
Australia
Level 2, 40 Kings Park Road
West Perth WA 6005
Australia
Tel: +61 8 9481 3188
Fax: +61 8 9321 1204
ABN: 84 144 581 519
www.stantons.com.au

31 August 2026

Board of Directors
Holista Colltech Limited
283 Rokeby Road,
Subiaco, WA 6008

Dear Directors

RE: HOLISTA COLLTECH LIMITED

In accordance with section 307C of the *Corporations Act 2001*, I am pleased to provide the following declaration of independence to the directors of Holista Colltech Limited.

As Audit Director for the review of the financial statements of Holista Colltech Limited for the half-year ended 30 June 2026, I declare that to the best of my knowledge and belief, there have been no contraventions of:

- (i) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- (ii) any applicable code of professional conduct in relation to the review.

Yours faithfully

STANTONS INTERNATIONAL AUDIT AND CONSULTING PTY LTD
(An Authorised Audit Company)

Waseem Akhtar
Director

Holista Colltech Limited

Contents

30 June 2026

Consolidated statement of profit or loss and other comprehensive income	7
Consolidated statement of financial position	8
Consolidated statement of changes in equity	9
Consolidated statement of cash flows	10
Condensed notes to the consolidated financial statements	11
Directors' declaration	18
Independent auditor's review report to the members of Holista Colltech Limited	19

General information

The financial statements cover Holista Colltech Limited (the "Company") as a Group (the "Group") consisting of Holista Colltech Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Holista Colltech Limited's functional and presentation currency.

Holista Colltech Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

Registered office

283 Rokeby Road
Subiaco
WA 6008
Australia

Principal place of business

Unit 1201, 12th Floor,
Amcorp Trade Centre, PJ Tower
No 18, Persiaran Barat,
46000 Petaling Jaya, Malaysia

A description of the nature of the Group's operations and its principal activities are included in the Directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 31 August 2026.

Holista Colltech Limited
Consolidated statement of profit or loss and other comprehensive income
For the half-year ended 30 June 2026

		Consolidated	
	Note	30 June 2026	30 June 2025
		\$	\$
Revenue			
Revenue		2,993,311	2,889,160
Other income	3	22,138	1,169
Expenses			
Change in inventories of finished goods and work in progress		(249,840)	4,818
Raw materials and consumables		(1,189,901)	(1,490,956)
Distribution costs and other costs of sales		(227,284)	(193,466)
Advertising and promotion		(114,389)	(152,219)
Consultancy and professional fees		(115,802)	(136,643)
Depreciation and amortisation		(20,317)	(26,884)
Employment costs		(768,389)	(1,034,725)
Finance costs		(52,933)	(58,184)
Foreign exchange gain		24,801	19,976
Impairment	4	21,093	162,365
Research and development		(13,148)	(24,814)
Other expenses	4	(249,625)	(236,792)
Legal Settlement	4	(2,595,357)	-
Loss before income tax expenses		(2,535,642)	(277,195)
Income tax (expense)/benefit		(26,324)	(19,374)
Loss after income tax expenses for the half-year		(2,561,966)	(296,569)
Other comprehensive income			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign currency translation		(1,868)	17,881
Other comprehensive income for the half-year, net of tax		(1,868)	17,881
Total comprehensive income for the half-year		<u>(2,563,834)</u>	<u>(278,688)</u>
Loss for the half-year is attributable to:			
Non-controlling interest		(976)	(2,005)
Owners of Holista Colltech Limited		(2,560,990)	(294,564)
		<u>(2,561,966)</u>	<u>(296,569)</u>
Continuing operations		(2,561,966)	(296,569)
Discontinued operations		-	-
		<u>(2,561,966)</u>	<u>(296,569)</u>
Total comprehensive income for the half-year is attributable to:			
Non-controlling interest		33,059	72,817
Owners of Holista Colltech Limited		(2,596,893)	(351,505)
		<u>(2,563,834)</u>	<u>(278,688)</u>
		Cents	Cents
Basic loss per share	12	(0.70)	(0.09)
Diluted loss per share	12	(0.70)	(0.09)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Holista Colltech Limited
Consolidated statement of financial position
As at 30 June 2026

		Consolidated	
	Note	30 June 2026 \$	31 December 2025 \$
Assets			
Current assets			
Cash and cash equivalents		564,563	2,160,771
Trade and other receivables	5	1,021,322	950,606
Inventories		805,593	1,099,817
Income tax recoverable		91,359	89,586
Other current assets	6	518,396	811,267
Total current assets		<u>3,001,233</u>	<u>5,112,047</u>
Non-current assets			
Property, plant, and equipment		705,113	741,038
Right-of-use assets		9,969	14,361
Intangible assets		<u>2,470</u>	<u>5,989</u>
Total non-current assets		<u>717,552</u>	<u>761,388</u>
Total assets		<u>3,718,785</u>	<u>5,873,435</u>
Liabilities			
Current liabilities			
Trade and other payables	7	5,061,494	4,434,150
Contract liabilities		309,957	258,951
Borrowings	8	933,254	1,166,799
Lease liability		8,280	8,304
Provisions		<u>12,602</u>	<u>12,691</u>
Total current liabilities		<u>6,325,587</u>	<u>5,880,895</u>
Non-current liabilities			
Borrowings	8	372,963	404,094
Lease liabilities		<u>2,137</u>	<u>6,514</u>
Total non-current liabilities		<u>375,100</u>	<u>410,608</u>
Total liabilities		<u>6,700,687</u>	<u>6,291,503</u>
Net liabilities		<u>(2,981,902)</u>	<u>(418,068)</u>
Equity			
Issued capital	9	25,717,958	25,717,958
Reserves		62,660	98,563
Accumulated losses		<u>(27,258,122)</u>	<u>(24,697,132)</u>
Equity attributable to the owners of Holista Colltech Limited		<u>(1,477,504)</u>	<u>1,119,389</u>
Non-controlling interest		<u>(1,504,398)</u>	<u>(1,537,457)</u>
Total equity		<u>(2,981,902)</u>	<u>(418,068)</u>

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

Holista Colltech Limited
Consolidated statement of changes in equity
For the half-year ended 30 June 2026

Consolidated	Issued capital \$	Foreign exchange translation reserve \$	Accumulated Losses \$	Non-controlling interest \$	Total equity \$
Balance at 1 January 2025	21,870,577	148,230	(23,748,211)	(1,638,316)	(3,367,720)
Loss after income tax expense for the half-year	-	-	(294,564)	(2,005)	(296,569)
Other comprehensive income for the half-year, net of tax	-	(56,941)	-	74,822	17,881
Total comprehensive income for the half-year	-	(56,941)	(294,564)	72,817	(278,688)
Proceeds from issue of shares	1,552,381	-	-	-	1,552,381
Balance at 30 June 2025	<u>23,422,958</u>	<u>91,289</u>	<u>(24,042,775)</u>	<u>(1,565,499)</u>	<u>(2,094,027)</u>

Consolidated	Issued capital \$	Foreign exchange translation reserve \$	Accumulated Losses \$	Non-controlling interest \$	Total equity \$
Balance at 1 January 2026	25,717,958	98,563	(24,697,132)	(1,537,457)	(418,068)
Profit/(Loss) after income tax expense for the half-year	-	-	(2,560,990)	(976)	(2,561,966)
Other comprehensive income for the half-year, net of tax	-	(35,903)	-	34,035	(1,868)
Total comprehensive income for the half-year	-	(35,903)	(2,560,990)	33,059	(2,563,834)
Shares issued during the half-year	-	-	-	-	-
Balance at 30 June 2026	<u>25,717,958</u>	<u>62,660</u>	<u>(27,258,122)</u>	<u>(1,504,398)</u>	<u>(2,981,902)</u>

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

Holista Colltech Limited
Consolidated statement of cash flows
For the half-year ended 30 June 2026

	Consolidated	
	30 June 2026	30 June 2025
	\$	\$
Cash flows from operating activities		
Receipts from customers	2,793,407	3,564,073
Payments to suppliers (inclusive of GST) and employees	(2,725,034)	(4,048,552)
Interest received	11,413	1,169
Finance costs	(52,933)	(58,184)
Net Income tax paid	(30,615)	(64,592)
Legal settlement and ASIC penalty	(1,436,357)	(900,000)
Net cash (used in) operating activities	(1,440,119)	(1,506,086)
Cash flows from investing activities		
Purchase of property, plant, and equipment	(214)	(6,290)
Increase of deposits/investments	117,618	(22,785)
Net cash (used in) investing activities	117,404	(29,075)
Cash flows from financing activities		
Proceeds from convertible loan note	-	1,552,381
Proceeds from borrowings	2,829,626	3,307,509
Repayment of borrowings	(3,050,444)	(3,291,597)
Repayment of lease liabilities	(3,982)	(3,812)
Net cash provided by financing activities	(224,800)	1,564,481
Net increase/(decrease) in cash and cash equivalents	(1,547,515)	29,320
Cash and cash equivalents at the beginning of the financial half-year	2,160,771	21,720
Effects of change in translation of foreign currency held	(48,693)	(9,293)
Cash and cash equivalents at the end of the financial half-year	<u>564,563</u>	<u>41,747</u>

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

Note 1. Material accounting policies

These general purpose financial statements for the interim half-year reporting period ended 30 June 2026 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 31 December 2025 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Note 1. Material accounting policies (continued)

Going concern

The financial report has been prepared on a going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the ordinary course of business.

For the half-year ended 30 June 2026, the Group recorded a loss after income tax of \$2,561,966 (30 June 2025: \$296,569) and net cash outflows from operating activities of \$1,440,119 (30 June 2025: \$1,506,086). As at 30 June 2026, the Group had cash and cash equivalents of \$564,563 (31 December 2025: \$2,160,771), net current liabilities of \$3,324,354 (31 December 2025: \$768,848) and net liabilities of \$2,981,902 (31 December 2025: \$418,068).

At 30 June 2026, the Group had total borrowings of \$1,306,217 (31 December 2025: \$1,570,893). Refer note 8 for more details.

As disclosed in Note 11, during the period the Group recognised a legal settlement expense of \$2,595,357 associated with the resolution of the Prolmmune matter. The matter was subsequently settled in full under a Deed of Settlement for US\$1.8 million, with the final settlement payment made subsequent to period end. The Directors consider the settlement of this longstanding matter to remove a significant source of uncertainty and future legal expenditure for the Group.

Included within trade and other payables is an accrued liability of approximately \$1.09 million relating to the reimbursement of ASIC legal costs.

The ability of the Group to continue as a going concern and meet its obligations as and when they fall due is dependent upon a number of factors, including:

- the Group's ability to generate positive operating cash flows from its existing operations, including achieving forecast sales growth through its Malaysian distribution network and maintaining effective cost controls;
- the Group's ability to effectively manage working capital, including inventory levels and supplier payment terms;
- the continued financial support of lenders, creditors and key stakeholders where required; and
- the Group's ability to obtain additional funding through equity raisings, convertible securities, debt facilities, strategic investments, joint venture arrangements or other corporate transactions if required.

Subsequent to balance date, on 9 July 2026, the Company entered into a binding terms sheet for an unsecured convertible loan of \$370,724 from Powerwind Plantation Sdn Bhd. The loan bears interest at 8% per annum and is convertible into ordinary shares at \$0.07 per share, subject to shareholder approval. Funds received under the facility were applied towards the final settlement payment associated with the Prolmmune matter.

In assessing the appropriateness of the going concern basis of preparation, the Directors have reviewed cash flow forecasts covering a period of at least 12 months from the date of approval of these financial statements. The forecasts include assumptions regarding the continued growth of the Group's supplements business, ongoing cost control measures, expected working capital management initiatives, and the availability of additional funding if required.

Based on these matters, the Directors have concluded that there are reasonable grounds to believe that the Group will be able to continue as a going concern and meet its obligations as and when they fall due for a period of at least 12 months from the date of approval of these financial statements.

Notwithstanding the above, the Group's net liability position, working capital deficiency, recurring operating cash outflows and ongoing funding requirements indicate the existence of a material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern. Should the Group be unable to generate sufficient cash flows from operations and/or obtain additional funding when required, it may be unable to realise its assets and discharge its liabilities in the ordinary course of business.

Note 1. Material accounting policies (continued)

Accordingly, a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern and therefore it may be unable to realise its assets and extinguish its liabilities in the normal course of business.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary should the Group be unable to continue as a going concern.

Note 2. Operating segments

Identification of reportable operating segments

The Group has identified its operating segments based on the internal reports that are provided to the Board of Directors (the Board) on a monthly basis and in determining the allocation of resources. Management has identified the operating segments based on the principal activities – Supplements; Ovine Collagen; Food Ingredients; Infection Control Solutions / Agriculture; Food Ingredients; and Corporate.

Segment Performance

	Supplements \$	Ovine Collagen \$	Food ingredients \$	Infection Control Solutions \$	Corporate \$	Total \$
Half-year ended 30 June 2025						
Revenue						
External sales	2,593,877	90,394	204,889	-	-	2,889,160
Other revenue	-	-	-	-	1,169	1,169
	<u>2,593,877</u>	<u>90,394</u>	<u>204,889</u>	<u>-</u>	<u>1,169</u>	<u>2,890,329</u>
Reconciliation of segment revenue to group revenue:						
Total group revenue and other income						<u>2,890,329</u>
Segment Profit/(Loss) from continuing operations before tax						
(Loss) before income tax expense	<u>167,316</u>	<u>5,246</u>	<u>(193,170)</u>	<u>167,134</u>	<u>(423,721)</u>	<u>(277,195)</u>

Holista Colltech Limited
Notes to the consolidated financial statements
30 June 2026

Note 2. Operating segments (continued)

	Supplements \$	Ovine Collagen \$	Food Ingredients \$	Infection Control Solutions \$	Corporate \$	Total
Half-Year ended 30 June 2026						
Revenue						
External sales	2,911,083	28,781	29,963	23,484	-	2,993,311
Other revenue	-	-	-	-	22,138	22,138
Total segment revenue	<u>2,911,083</u>	<u>28,781</u>	<u>29,963</u>	<u>23,484</u>	<u>22,138</u>	<u>3,015,449</u>
Reconciliation of segment revenue to group revenue: Total group revenue and other income						<u>3,015,449</u>
Segment Gain/(Loss) from continuing operations before tax Gain/(Loss) before income tax expense	<u>614,871</u>	<u>(15,696)</u>	<u>(235,284)</u>	<u>26,089</u>	<u>(2,925,622)</u>	<u>(2,535,642)</u>

Segment Financial Position

	Supplement s \$	Ovine Collagen \$	Food Ingredients \$	Infection Control Solutions \$	Corporate \$	Total \$
As at 30 June 2025						
Segment Assets	2,636,133	63,098	1,506,275	714	32,214	4,238,434
Intra-segment eliminations	-	-	(712,155)	-	26,776	(684,379)
Total assets	<u>2,636,133</u>	<u>63,098</u>	<u>794,120</u>	<u>714</u>	<u>58,990</u>	<u>3,553,055</u>
Segment liabilities	(3,258,323)	(2,370,542)	(3,070,917)	(381,521)	(28,389)	(9,109,692)
Intra-segment eliminations	-	-	320,701	-	3,141,909	3,462,610
Total liabilities	<u>(3,258,323)</u>	<u>(2,370,542)</u>	<u>(2,750,216)</u>	<u>(381,521)</u>	<u>3,113,520</u>	<u>(5,647,082)</u>
Total net assets/(liabilities)	<u>(622,190)</u>	<u>(2,307,444)</u>	<u>(1,955,096)</u>	<u>(380,807)</u>	<u>3,171,510</u>	<u>(2,094,027)</u>

Holista Colltech Limited
Notes to the consolidated financial statements
30 June 2026

Note 2. Operating segments (continued)

	Supplements \$	Ovine Collagen \$	Food Ingredients \$	Infection Control Solutions \$	Corporate \$	Total \$
As at 30 June 2026						
Segment Assets	2,317,150	95,920	1,907,705	677	39,472	4,360,924
Intra-segment eliminations	-	-	(690,005)	-	47,866	(642,139)
Total assets	<u>2,317,150</u>	<u>95,920</u>	<u>1,217,700</u>	<u>677</u>	<u>87,338</u>	<u>3,718,785</u>
Segment Liabilities	(2,630,718)	(4,477,361)	(2,554,298)	(342,116)	(60,234)	(10,064,727)
Intra-segment eliminations	-	-	327,984	-	3,036,056	3,364,039
Total liabilities	<u>(2,630,718)</u>	<u>(4,477,361)</u>	<u>(2,226,314)</u>	<u>(342,116)</u>	<u>2,975,822</u>	<u>(6,700,687)</u>
Total net assets/(liabilities)	<u>(313,568)</u>	<u>(4,381,441)</u>	<u>(1,008,614)</u>	<u>(341,439)</u>	<u>3,063,160</u>	<u>(2,981,902)</u>

Note 3. Other income

	Consolidated 30 June 2026	30 June 2025
	\$	\$
Rental income	10,725	-
Interest income	11,413	1,169
Total other income	<u>22,138</u>	<u>1,169</u>

Note 4. Loss before income tax

	Consolidated 30 June 2026	30 June 2025
	\$	\$
Loss before income tax includes the following specific expenses:		
<i>Impairment</i>		
Reversal of impairment on credit losses (Note 5)	(21,093)	(162,365)
	(21,093)	(162,365)
<i>Other expenses</i>		
Compliance and regulatory costs	68,734	68,989
Insurance	11,890	10,891
Other expenses	5,362	10,303
Stock written-off	23,301	-
Collie factory maintenance costs	1,091	976
Audit fees	62,123	65,074
Operating lease and rental expense	77,124	80,559
	<u>249,625</u>	<u>236,792</u>
ProlImmune legal settlement		
Initial payment US\$1,000,000 paid on 22 April 2026	1,436,357	-
Final payment US\$800,000 paid on 10 July 2026	1,159,000	-
	<u>2,595,357</u>	<u>-</u>

Holista Colltech Limited
Notes to the consolidated financial statements
30 June 2026

Note 5. Trade and other receivables

	Consolidated	
	30 June	31 December
	2026	2025
	\$	\$
<i>Current assets</i>		
Trade receivables	1,180,898	1,146,681
Less: Allowance for expected credit losses	<u>(275,451)</u>	<u>(313,646)</u>
	905,447	833,035
Other receivables	58,551	58,739
Amounts advanced to third party	475,157	475,157
Less: allowance for expected credit losses	<u>(475,157)</u>	<u>(475,157)</u>
Interest receivable	57,324	58,832
	<u>1,021,322</u>	<u>950,606</u>

During the period ended 30 June 2025, the Group received RM450,686 (AUD162,365) from related party iGalen Inc, which represents recovery of outstanding debt.

The average credit period on sales of goods ranges from 30 to 90 days. Amounts are considered as 'past due' when the debt has not been settled, within the terms and conditions agreed between the Group and the customer or counter party to the transaction.

Note 6. Other current assets

	Consolidated	
	30 June	31 December
	2026	2025
	\$	\$
<i>Current assets</i>		
Prepayments	77,288	95,171
Security deposits	227,682	355,366
Other deposits	16,093	21,293
Right of return assets	<u>197,333</u>	<u>339,437</u>
	<u>518,396</u>	<u>811,267</u>

Security deposits are restricted cash. In order to obtain various financing facilities, banks in Malaysia require cash to be deposited if other collateral is not available. These deposits are interest bearing and the interest is compounded and added to the principal.

Holista Colltech Limited
Notes to the consolidated financial statements
30 June 2026

Note 7. Trade and other payables

	Consolidated	
	30 June 2026	31 December 2025
	\$	\$
<i>Current liabilities</i>		
Trade payables	1,500,834	1,478,126
Accruals*	2,684,563	1,559,696
Other payables - current	99,040	420,717
Refund liability	736,888	934,345
Dividends payable	25,071	25,730
Amount Due To Director	15,098	15,536
	<u>5,061,494</u>	<u>4,434,150</u>

*Accruals includes ProImmune legal settlement of \$1.159 million and ASIC legal reimbursement of \$1.09 million

Note 8. Borrowings

	Consolidated	
	30 June 2026	31 December 2025
	\$	\$
<i>Current liabilities</i>		
Term Loan	40,932	41,175
Trade Facilities	876,704	1,110,048
Loan from third party	15,618	15,576
	<u>933,254</u>	<u>1,166,799</u>
<i>Non-current liabilities</i>		
Term loan	<u>372,963</u>	<u>404,094</u>

Note 9. Issued capital

	Consolidated			
	30 June 2026	31 December 2025	30 June 2026	31 December 2025
	Shares	Shares	\$	\$
Fully paid ordinary shares	<u>367,834,364</u>	<u>367,834,364</u>	<u>25,717,958</u>	<u>25,717,958</u>

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the Company in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote. Ordinary shares have no par value and the company does not have a limited amount of authorised capital.

Note 10. Dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

Note 11. Contingent liabilities

The Prolmmune Company, LLC ("Prolmmune")

As disclosed in prior financial reports, the Company was party to litigation with Prolmmune arising from alleged breaches of supply contracts, which resulted in a US judgment against the Company. Following affirmation of the judgment by the United States Court of Appeals for the Second Circuit on 20 February 2025 (fixing the amount owing, inclusive of interest and attorney's fees, at US\$2,063,141.05), Prolmmune sought to enforce the judgment in the Supreme Court of Western Australia (CIV 1440 of 2025), which the Company contested, while also bringing its own counter-proceedings (CIV 1332 of 2025).

On 7 April 2026, the Supreme Court of Western Australia (Palmer J) delivered judgment in *The Prolmmune Company, LLC v Holista Colltech Limited* [2026] WASC 112, granting summary judgment in favour of Prolmmune and enforcing the US judgment debt. The Board subsequently resolved to settle the matter in full for US\$1,800,000 — a material discount to the total judgment debt plus accruing interest and legal fees — under a Deed of Settlement dated 22 April 2026, comprising an initial payment of US\$1,000,000 on execution and a balance of US\$800,000 payable by mid-July 2026. The settlement resolved all claims between the parties, including the Company's own claim against Prolmmune for misleading or deceptive conduct.

The final payment of US\$800,000 was made on 10 July 2026, completing all amounts due under the settlement. With the settlement paid in full, the Company considers this matter fully resolved, with no further contingent liability recognised in respect of the judgment debt as at the date of this report.

Atkinson legal-fee proceeding

On 20 July 2026, Atkinson Corporate Lawyers Pty Ltd commenced proceedings in the District Court of Western Australia against Holista Colltech Limited in relation to legal fees and counsel fees allegedly outstanding for services provided in connection with the Prolmmune matter. The plaintiff claims \$86,025.50, together with interest and costs.

As at 30 June 2026, the Company had recognised \$60,053.60 in trade and other payables in respect of the relevant legal fees. Accordingly, the additional disputed principal amount claimed is \$25,971.90, excluding any interest and costs that may be awarded.

The Company disputes the additional amount claimed and, through its legal advisers, has requested supporting invoices, documents and further particulars. No provision has been recognised for the additional disputed amount because the proceeding remains at an early stage and, based on the information presently available, the outcome of the proceeding and the amount, if any, of any additional obligation cannot be reliably determined.

Note 12. Earnings per share

	Consolidated	
	30 June 2026	30 June 2025
	\$	\$
Loss after income tax	(2,561,966)	(296,569)
Non-controlling interest	976	2,005
Loss after income tax attributable to the owners of Holista Colltech Limited	(2,560,990)	(294,564)

Note 12. Earnings per share (continued)

	Number	Number
Weighted average number of ordinary shares outstanding during the period used in calculation of basic EPS	367,834,364	316,261,613
Weighted average number of ordinary shares outstanding during the period used in calculation of basic EPS	367,834,364	316,261,613
	Cents	Cents
Basic loss per share	(0.70)	(0.09)
Diluted loss per share	(0.70)	(0.09)

There are no options and performance rights outstanding as at the end of the financial period.

Note 13. Subsequent events

As announced to the ASX on 22 April 2026, the Supreme Court of Western Australia granted summary judgment in favour of Prolmmune, enforcing the US judgment debt of US\$2,063,141.05. The Company subsequently settled the matter in full for US\$1.8 million, with final payment completed on 10 July 2026. Refer to Note 11 for further details.

On 9 July 2026, the Company entered into a binding terms sheet for an unsecured convertible loan of A\$370,724 from Powerwind Plantation Sdn Bhd, at 8% per annum interest, convertible into fully paid ordinary shares at A\$0.07 per share (5,296,055 shares), subject to shareholder approval, with proceeds applied towards the final settlement payment to Prolmmune referred to above.

Note 14. Related party Transactions

Other than the compensation of key management personnel in the ordinary course of business and the formation of the Ovicoll Pty Ltd joint venture with Swang Chai Chuan Limited ("SCC") referred to in Note 15, there were no other material related party transactions during the half-year ended 30 June 2026.

Note 15. Interest in joint venture

On 4 May 2026, the Group entered into a joint venture agreement with SCC to establish Ovicoll Pty Ltd ("Ovicoll"), in which the Group holds a 50% interest. Ovicoll was established to develop a collagen manufacturing facility in Collie, Western Australia. Ovicoll is jointly controlled by the Group and SCC and is accounted for as a joint venture using the equity method in accordance with AASB 128 Investments in Associates and Joint Ventures.

The Group's contribution to Ovicoll comprised intellectual property, which had a nil carrying value in the Group's accounting records at the date of contribution. Accordingly, the carrying value of the Group's investment in Ovicoll as at 30 June 2026 is nil.

Ovicoll incurred a loss of approximately \$64,000 for the period from incorporation to 30 June 2026. In accordance with AASB 128, the Group has not recognised its 50% share of this loss (approximately \$32,000), as the carrying amount of its investment in Ovicoll has already been reduced to nil and the Group has no legal or constructive obligation to fund further losses incurred by Ovicoll.


Holista Colltech Limited
Directors' declaration
30 June 2026

In the directors' opinion:

- the attached consolidated financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached consolidated financial statements and notes give a true and fair view of the Group's financial position as at 30 June 2026 and of its performance for the financial half-year ended on that date; and
- subject to the going concern matter noted in Note 1, there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors



LEONG MAN LOONG
Executive Director and Chief Executive Officer

31 August 2026

**INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF
HOLISTA COLLTECH LIMITED**

Report on the Half-Year Financial Report

Conclusion

We have reviewed the half-year financial report of Holista Colltech Limited (the "Company") and its subsidiaries (the "Group"), which comprises the consolidated statement of financial position as at 30 June 2026, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, condensed notes comprising a summary of material accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Holista Colltech Limited does not comply with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the Group's financial position as at 30 June 2026 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the Auditor's *Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* has been given to the directors of the Company on 31 August 2026.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 to the half-year financial report, which indicates that the Group incurred a loss after tax of \$2,561,966, a net cash outflow from operating activities of \$1,440,119. As at 30 June 2026, the Group had cash and cash equivalents of \$564,563, a working capital deficiency of \$3,324,354 and net liabilities of \$2,981,902. As stated in Note 1, these events or conditions, along with other matters set forth in Note 1, indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern.

Our conclusion is not modified in respect of this matter.



Responsibility of the Directors for the Financial Report

The directors of Holista Colltech Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 30 June 2026 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

STANTONS INTERNATIONAL AUDIT AND CONSULTING PTY LTD
(An Authorised Audit Company)

Stantons International Audit & Consulting Pty Ltd
Waseem Akhtar

Waseem Akhtar
Director

West Perth, Western Australia
31 August 2026